

MBF Therapeutics
Developing next generation Immunotherapeutics for infectious diseases and cancer for the animal and human health market using gene based check point inhibitors.
- Stage Full Product Ready
- Industry Biotechnology
- Location Ambler, PA, US
- Currency USD
- Founded June 2008
- Employees 4
- Incorporation Type C-corp
- Website mbftherapeutics.com
Company Summary
MBFT is a life science company developing an innovative platform to deliver safe and effective immunotherapeutic DNA vaccines. These vaccines elicit potent and durable protective immunity against infectious diseases and provide new therapeutic treatments for cancer. We are translating the concept of T cell vaccines from human health to the veterinary field, where stimulating a cell mediated immune response is an innovation urgently needed.
Team
-
Founder & CEO
CEO of RHeoGene. Started the company in 1999 as a JV between Rohm & Haas and Argonex. In 2003, he led the highly innovative and unique effort to donate the IP and material assets of RHeoGene to the UPMC. As RheoGene CEO, he and his team established an innovative clinical development program with the RheoSwitch® Therapeutic System (RTS) that has led to the first human clinical trial of a small molecule-induced gene regulation system.
-
Chief Scientific Officer
Founder & VP Marketing and Communications @ RheoGene
Co-founder Immunotope
Portfolio Manager, Biostrategy Partners
Rohm and Haas Co. -
Chief Medical Officer
CEO at Prairie Diagnostic Services, Inc., a full service veterinary diagnostic laboratory
Chief Medical Officer at Premune
Schering-Plough Animal Health, Pfizer AH (international HQ), Intervet, Inc., Baxter HealthCare and Merial
DVM from Cornell University -
Executive Vice President Business Development
President of Amlan International the Animal Health and Nutrition Division of family owned publicly traded sorbent mineral company from Chicago, Illinois.
NOVARTIS ANIMAL VACCINES INC., President & CEO
PFIZER ANIMAL HEALTH Marketing Director/Senior Marketing Manger, Global Biologicals
SMITHKLINE BEECHAM ANIMAL HEALTH Director, Worldwide Strategic Product Development
Previous Investors
-
Ben Franklin Technology Partners SEPAUnconfirmedChris CashmanUnconfirmedGerald McNamaraUnconfirmed